Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Corazon (Corsee) D. Sanders Sells 584 Shares

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Corazon (Corsee) D. Sanders sold 584 shares of the business’s stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $40.98, for a total transaction of $23,932.32. Following the completion of the transaction, the director now directly owns 12,009 shares of the company’s stock, valued at approximately $492,128.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Ultragenyx Pharmaceutical Trading Down 1.8 %

Shares of Ultragenyx Pharmaceutical stock traded down $0.75 during trading hours on Wednesday, reaching $40.21. The stock had a trading volume of 638,254 shares, compared to its average volume of 823,300. The stock’s 50 day moving average is $41.16 and its 200 day moving average is $44.99. The firm has a market capitalization of $3.34 billion, a PE ratio of -5.01 and a beta of 0.56. Ultragenyx Pharmaceutical Inc. has a twelve month low of $31.52 and a twelve month high of $54.56.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.31). Ultragenyx Pharmaceutical had a negative return on equity of 425.63% and a negative net margin of 138.58%. The firm had revenue of $108.83 million during the quarter, compared to analyst estimates of $116.03 million. During the same quarter last year, the company posted ($2.33) EPS. The company’s revenue was up 8.3% on a year-over-year basis. As a group, sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

RARE has been the topic of several analyst reports. JPMorgan Chase & Co. lifted their price target on shares of Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, March 18th. TD Cowen lifted their price target on shares of Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $115.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, June 12th. The Goldman Sachs Group raised shares of Ultragenyx Pharmaceutical from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $56.00 to $67.00 in a report on Thursday, June 6th. Finally, Canaccord Genuity Group lifted their price target on shares of Ultragenyx Pharmaceutical from $109.00 to $111.00 and gave the stock a “buy” rating in a report on Friday, May 31st. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $86.71.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of RARE. Sands Capital Management LLC raised its position in shares of Ultragenyx Pharmaceutical by 59.8% during the 4th quarter. Sands Capital Management LLC now owns 4,118,008 shares of the biopharmaceutical company’s stock worth $196,923,000 after purchasing an additional 1,540,791 shares during the last quarter. RTW Investments LP raised its holdings in Ultragenyx Pharmaceutical by 27.4% in the 4th quarter. RTW Investments LP now owns 6,887,086 shares of the biopharmaceutical company’s stock valued at $329,340,000 after acquiring an additional 1,481,997 shares during the last quarter. Vanguard Group Inc. raised its holdings in Ultragenyx Pharmaceutical by 19.9% in the 4th quarter. Vanguard Group Inc. now owns 8,673,432 shares of the biopharmaceutical company’s stock valued at $414,764,000 after acquiring an additional 1,440,264 shares during the last quarter. Norges Bank acquired a new stake in Ultragenyx Pharmaceutical in the 4th quarter valued at about $36,846,000. Finally, Avoro Capital Advisors LLC raised its holdings in Ultragenyx Pharmaceutical by 137.1% in the 1st quarter. Avoro Capital Advisors LLC now owns 830,000 shares of the biopharmaceutical company’s stock valued at $38,753,000 after acquiring an additional 480,000 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.